EDN1 and hepatocellular carcinoma: Apart from being a recognized vasoconstrictor peptide, clinical studies reported that plasma concentration of EDN1 was markedly increased in both HCC patients and patients with metastasized tumors in the liver and that 70% (n = 14/20) of HCC samples showed EDN1 expression.97, 98